# US 8,277,776 B2 · Compositions for delivery of therapeutics and other materials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,776 B2
- Document ID: US8277776B2
- Status: Granted
- Kind: B2
- Application number: 12/625,498
- Filed: 2009-11-24
- Published: 2010-06-24
- Granted: 2012-10-02
- Earliest claimed: 2002-02-27
- Assignees: PharmaIN Corporation
- Inventors: Elijah M. Bolotin; Gerardo M. Castillo
- Web page: https://patentgrep.com/patent/US8277776B2

## CPC

- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/6911: {the form being a liposome}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.

## Claims

### Claim 1

A method of delivering an active agent to a target site comprising administering a composition to a subject, the composition comprising:
a first molecule comprising:
a first hydrophobic group comprising a first metal binding domain (FMBD);
a metal ion chelated to the FMBD; and
an active agent comprising a second MBD (SMBD) coordinately bonded to said metal ion; and
a second molecule comprising:
a second hydrophobic group; and
a first hydrophilic group covalently linked to the second hydrophobic group:
wherein after administration of the composition to said subject, the active agent is released in a sustained manner.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises:
a targeting group covalently linked to the hydrophilic group.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises a third molecule comprising:
a third hydrophobic group:
a second hydrophilic group comprising a first and second end, with the first end covalently linked to the third hydrophobic group; and
a targeting group covalently linked to the second end of the second hydrophilic group.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises:
a third metal binding domain (TMBD) covalently linked to the second hydrophobic group.

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition further comprises a third molecule comprising:
a third hydrophobic group;
a second hydrophilic group, comprising a first and second end, with the first end covalently linked to the third hydrophobic group; and
a targeting group covalently linked the second hydrophilic group.

### Claim 6 (depends on 4)

The method of claim 4 wherein the composition further comprises:
a targeting group covalently linked the first hydrophilic group.

### Claim 7 (depends on 6)

The method of claim 6 wherein the composition further comprises a third molecule comprising:
a third hydrophobic group;
a second hydrophilic group covalently linked to the third hydrophobic group.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of claims 1-7, wherein the FMBD, the SMBD, or the TMBD is selected from a nitrogen containing poly carboxylic acid, or a polypeptide.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of claims 1-7, wherein the metal ion is a transition metal ion (d-block of the periodic table).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of claims 1-7, wherein the active agent is a therapeutic agent.

### Claim 11 (depends on 2, 3, 5, 6)

The method of one of claims 2, 3, 5, 6, or 7, wherein the targeting group is selected from a group consisting of an antibody, a cell surface receptor ligand, a cell surface receptor binding drug, a cell surface binding saccharide ligand, an extracellular matrix ligand, a cytosolic receptor ligand, a growth factor, cytokine, incretin, a hormone, and lectin.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of the claims 1-7, wherein the FMBD, the SMBD, or the TMBD are individually selected from N-(hydroxyl-ethyl)ethylenediaminetriacetic acid;
Nitrilotriacetic acid (NTA); Ethylenebis(oxyethylenenitrilo) tetraacetic acid;
1,4,7,10 tetraazacyclodo-decane-N,N′,N″,N′″-tetraacetic acid; 1,4,7,10, tetraaza-cyclododecane-N,N′,N″-triacetic acid; 1,4,7-tris(carboxymethyl)-10-(2′-hydroxypropyl)-1,4,7,10-tetraazocydodecane; 1,4,7-triazacyclonane-N,N′,N″triacetic acid; 1,4,8,11 tetraazacyclotetra-decane-N,N′,N″,N′″-tetraacetic acid; diethylenetriamine-entaacetic acid (DTPA);
ethylenedicysteine; bis(aminoethanethiol)carboxylic acid; triethylenetetraamine-hexaacetic acid;
ethylenediamine-tetraacetic acid (EDTA); 1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid; or metal binding polypeptide.

### Claim 13 (depends on 8)

The method of claim 8, wherein the FMBD, the SMBD, or the TMBD is a metal binding polypeptide of formula: (AxHy)p where A is any amino acid, H is histidine, x is an integer from 0-6, y is an integer from 1-6, and p is an integer from 1-6.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of the claims 1-7, wherein the hydrophobic group has a molecular weight ranging from about 50 to about 1000 Daltons.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of the claims 1-7, wherein the first, the second, or the third hydrophobic group comprises one or more linear fatty acyl groups with formula [CH3(CH2)xC0-] where x is an integer from 6-50.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of the claims 1-7, wherein the first, the second, or the third hydrophobic group is a branched or straight chain C5-C50 alkyl, a substituted branched or straight chain C5-C50 alkyl, a poly-glycine, a substituted poly-glycine, poly-alanine, poly-valine, poly-leucine, poly-isoleucine, poly-phenylalanine, poly-proline, poly-methionine, phenyl, napthyl, cholesterol, vitamin D, or vitamin E.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of claims 1-7, wherein the first, the second, or the third hydrophobic group has a general formula [PvNwCxHyOz-] where v is an integer from 0-3, w is an integer from 0-3, x is an integer from 8-48, y is an integer from 15-95; and z is an integer from 1-13.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of one of the claims 1-7, wherein the first or the second hydrophilic group comprises a polymer selected from poly(ethylene glycol); alkoxy poly(ethylene glycol); methoxy poly(ethylene glycol); dicarboxylic acid esterified poly(ethylene glycol) monoester; poly(ethylene glycol)-diacid; copolymer of poly(ethylene glycol); poly(ethylene glycol) monoamine; methoxy poly(ethylene glycol) monoamine; methoxy poly(ethylene glycol) hydrazide; methoxy poly(ethylene glycol) imidazolide; block copolymer of poly (ethylene glycol);
poly-lactide-glycolide co-polymer; polysaccharide; oligosaccharides; polyamidoamine; and
polyethyleneimine.

### Claim 19 (depends on 1)

The method of claim 1 wherein the route of administration is intravenous.

### Claim 20 (depends on 1)

The method of claim 1 wherein the active agent is a peptide.

### Claim 21 (depends on 1)

The method of claim 1 wherein the subject is in need of treatment of an inflammatory disease wherein the inflammatory disease is rheumatoid arthritis.

### Claim 22 (depends on 21)

The method of claim 21 wherein the route of administration is parenteral.
